Presently, over 65 companies claim to offer drug repurposing-related services to the global pharmaceutical industry

Repurposing of marketed / shelved / pipeline candidates for the treatment of diseases (different from original target indications) has emerged as a viable business strategy. The rising popularity of this approach can further be attributed to various benefits, such as reduced development timelines, decreased investments and relatively higher success rates (considering that the safety profiles of such candidates have already been established).

• A detailed assessment of the current market landscape of companies offering drug repurposing services based on several relevant parameters, including year of establishment, company size, location of headquarters, type of company, type of service offered (drug discovery, consulting and others), purpose of repurposing, type of repurposing and technology platform used.
• A detailed analysis of the various partnerships that have been signed within this domain, during the period 2013-2020, along with information on year of partnership, type of partnership, and partner company, type of technology / platform used, and key value drivers (such as target therapeutic area and type of drug molecule) and location of collaborators.
• A review of recent initiatives undertaken by big pharma players across the globe for the discovery and development of repurposed drugs, along with information on number of initiatives, year of initiative. It also features a benchmark analysis of top 11 big pharma players (in terms of annual revenues of 2019), comparing them across various relevant parameters, such as name of repurposed drug, drug class, target therapeutic area, phase of development and target patient population.
• A detailed analysis of terminated / withdrawn / suspended drug candidates that can be repurposed, based on several relevant parameters, such as current recruitment status, trial phase, cause of discontinuation of trial, type of sponsor, target therapeutic area(s).
• A detailed analysis on the cost saving potential of drug repurposing approaches, as compared to the traditional de novo drug development methods.
• Elaborate profiles of key players that specialize in offering services for the development of repurposed drugs. Each profile features an overview of the company (including information on its year of establishment, company size and location of headquarters), details on type of technology platform used, drug discovery and repurposing focused service portfolio, and an informed future outlook.

To order this 250+ page report, which features 100+ figures and 140+ tables, please visit this link

The USD 1.2 billion (by 2030) financial opportunity within the drug repurposing service providers market has been analyzed across the following segments:

• Type of Repurposing Approaches
• Disease-centric approach
• Target-centric approach
• Drug-centric approach
• Therapeutic Area
• Same Therapeutic Area
• Different Therapeutic Area
• Type of Drug Molecule
• Biologics
• Small Molecule
• Key Geographical Region
• North America
• Europe
• Asia-Pacific

The Drug Repurposing Service Providers Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Auxillis Pharma
• ChemBio Discovery Solutions
• Excelra
• GVK Bio
• Iris Pharma
• Lantern Pharma
• PanXome
• Pharmacelera
• Physiogenex
• Smart Pharma
• Socium
• SOM Biotech

Table of Contents

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape
 

5. Role of Non-Profit / Academic Organizations

6. Company Profiles
 

7. Partnerships
 

8. Big Pharma Initiatives
 

9. Case Study: Discontinued Drug Development Programs
 

10. Cost Saving Analysis
 

11. Market Forecast and Opportunity Analysis
 

12. Covid-19 Impact on Drug Repurposing Service Providers Market
 

13. Recent Advancements and Trends in Outsourcing of Drug Repurposing

14. Interview Transcripts

15. Appendix 1: List of Potential Drug-Indication Candidates for Drug Repurposing

16. Appendix 2: Tabulated Data

17. Appendix 3: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]